SPIOMET4HEALTH, NCT05394142 / 2021-003177-58: A Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) in Polycystic Ovary Syndrome (PCOS) |
|
|
| Recruiting | 2 | 364 | Europe, RoW | Placebo, Pioglitazone, PIO, Spironolactone, S, Metformin, MET | Fundació Sant Joan de Déu | Polycystic Ovary Syndrome (PCOS) | 04/25 | 04/25 | | |
| Recruiting | N/A | 100 | Europe, US | Metreleptin | Aegerion Pharmaceuticals, Inc. | Generalised Lipodystrophy, Partial Lipodystrophy | 10/31 | 10/31 | | |
| Recruiting | N/A | 5000 | Europe, RoW | | University of Ulm, Sorbonne University, University Hospital, Lille, University of Cambridge, Endocrinology Research Centre, Moscow, University of Leipzig, University of Amsterdam, Dokuz Eylul University, IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Rome Tor Vergata, University of Pisa, University of Santiago de Compostela, Università degli Studi del Piemonte Orientale Amedeo Avogadro, University Hospital Muenster, Szeged University, Centro Hospitalar do Porto, University Medical Centre Ljubljana, Medical University of Vienna, Ostschweizer Kinderspital | Lipodystrophy Acquired, Lipodystrophy Congenital | 01/68 | 01/68 | | |
